Austin, TX – [Insert Date of Publication] – Hanger Inc., a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, has announced the strategic acquisition of Liberating Technologies Inc. (LTI). This pivotal move is set to significantly bolster Hanger’s research and innovation capabilities, accelerating the development and deployment of cutting-edge prosthetic technologies designed to profoundly enhance the lives of O&P patients worldwide. The acquisition solidifies Hanger’s commitment to advancing clinical practice through evidence-based care and fostering a future where technological breakthroughs translate directly into improved functional outcomes and quality of life for individuals with limb loss.
This acquisition brings LTI, a distinguished research organization with a robust history of securing government-funded grants for high-impact O&P concepts, fully into the Hanger ecosystem. Previously owned by Coapt, a company Hanger announced its intent to acquire in 2025, LTI’s integration completes the full Coapt portfolio under Hanger’s umbrella. The combined strength of LTI’s specialized research team and Hanger’s extensive clinical network promises an unparalleled synergy, poised to drive the next wave of innovation in the orthotic and prosthetic field.
A Strategic Expansion: Hanger’s Vision for Innovation
Hanger Inc. has long been at the forefront of patient care and innovation within the orthotics and prosthetics industry. With a nationwide network of clinics and a steadfast commitment to improving patient outcomes, the company continually seeks avenues to integrate advanced technologies and evidence-based practices into its services. The acquisition of Liberating Technologies Inc. (LTI) represents a significant leap forward in this ongoing mission, underscoring Hanger’s dedication to not only providing exceptional care today but also shaping the future of O&P solutions.
Pete Stoy, Hanger’s Chief Executive Officer, articulated the profound strategic importance of this acquisition. "The addition of LTI strengthens Hanger’s continued commitment to expanding research and development, advancing clinical practice, and improving patient outcomes through evidence-based care," Stoy remarked. His statement highlights a multi-faceted objective: to deepen Hanger’s internal R&D capabilities, to elevate the standard of clinical practice across the industry, and to ensure that all advancements are rigorously supported by scientific evidence, ultimately benefiting the patient.
Furthermore, Stoy emphasized the global aspirations embedded within this strategic partnership. "This partnership also reflects our ambition to accelerate global technological progress for O&P patients and to join forces with current and future collaborators to drive the next generation of innovation," he added. This vision extends beyond internal development, signaling Hanger’s intent to foster a collaborative environment where diverse expertise can converge to tackle complex challenges in prosthetic design and functionality. By bringing LTI’s specialized research talent into its fold, Hanger is not merely acquiring a company; it is investing in a future where technological barriers are systematically dismantled, leading to more intuitive, comfortable, and effective prosthetic devices.
The integration of LTI will seamlessly align with Hanger’s existing innovation infrastructure, notably Hanger Ventures and the Hanger Institute for Clinical Research and Education. Hanger Ventures serves as the company’s strategic arm for identifying and investing in emerging technologies and innovative solutions that complement Hanger’s core business and mission. It acts as an incubator and accelerator for promising concepts, facilitating their transition from theoretical potential to practical application. The Hanger Institute, on the other hand, is dedicated to generating and disseminating clinical evidence, conducting robust research, and providing educational resources to advance O&P practice. It bridges the gap between scientific discovery and clinical implementation, ensuring that new technologies are thoroughly vetted and effectively integrated into patient care protocols.
By positioning LTI within this established ecosystem, Hanger aims to create a dynamic feedback loop. LTI’s research team will gain direct access to Hanger’s vast clinical insights and patient data, invaluable resources that can inform and refine their research directions. Conversely, Hanger’s clinical professionals will benefit from early exposure to groundbreaking technologies, enabling them to provide input during the development phase and prepare for the integration of these innovations into their practice. This synergistic approach is designed to shorten development cycles, enhance the relevance of research outcomes, and ultimately deliver superior solutions to patients with greater efficiency.
Liberating Technologies Inc.: A Legacy of Pioneering Research
Liberating Technologies Inc. (LTI), founded in 2000, has carved out a significant niche as a highly specialized research organization within the orthotics and prosthetics landscape. Its foundational mission has been to push the boundaries of what is possible in prosthetic technology, driven by a deep commitment to improving the lives of individuals with limb differences. Unlike many commercial entities, LTI’s operational model has primarily revolved around securing and executing government-funded grants, a testament to the recognized caliber and potential impact of its research proposals.
Since 2008, LTI’s dedicated team of researchers and engineers has consistently demonstrated an exceptional ability to conceptualize and develop "cutting-edge, high-impact concepts." These concepts are not merely incremental improvements but often represent paradigm shifts in how prosthetic devices function, interact with the user, and integrate into daily life. The reliance on government funding underscores the strategic importance of LTI’s work, often addressing national health priorities and military veteran care needs through advanced technological solutions. This funding mechanism also implies a rigorous peer-review process, validating the scientific merit and potential for real-world application of LTI’s projects.
LTI’s portfolio of research initiatives has historically focused on addressing some of the most persistent challenges faced by prosthesis users. These include enhancing control and dexterity, improving comfort and skin health at the residual limb-socket interface, and optimizing the intuitive interaction between the user and their device. Their work has often ventured into interdisciplinary fields, leveraging advances in areas such as signal processing, materials science, and human-machine interface design to create truly innovative solutions.
The impact of LTI’s work on the broader O&P field cannot be overstated. By developing next-generation technologies, they have not only provided direct solutions but have also stimulated further research and development across the industry. Their breakthroughs often serve as benchmarks, inspiring other researchers and manufacturers to pursue similar levels of innovation. Their specialized expertise in navigating the complexities of grant-funded research has also made them a unique and valuable asset, capable of tackling long-term, high-risk, high-reward projects that might be beyond the scope or immediate commercial interest of other organizations.
The acquisition by Hanger Inc. therefore represents a critical juncture for LTI. While maintaining its core identity and focus on grant-funded research, LTI will now benefit from the extensive resources and clinical reach of a national leader in O&P care. This new affiliation promises to provide LTI’s researchers with unprecedented access to clinical data, patient feedback, and technical support, allowing them to refine their innovations with a deeper understanding of real-world needs and challenges. The ability to directly test and iterate prototypes within Hanger’s clinical settings will undoubtedly accelerate the translation of laboratory discoveries into practical, patient-ready solutions, amplifying LTI’s legacy of pioneering research.
The Chronology of Integration: From Coapt to LTI
The integration of Liberating Technologies Inc. into the Hanger family is not an isolated event but rather the culmination of a broader strategic initiative that began with Hanger’s earlier acquisition announcement regarding Coapt. In 2025, Hanger publicly declared its impending acquisition of Coapt, a company renowned for its advanced control systems for upper-limb prostheses. This initial move signaled Hanger’s commitment to enhancing the intelligent capabilities of prosthetic devices, particularly in the realm of intuitive control and user interface.
Coapt had established itself as a leader in pattern recognition control, a sophisticated technology that allows prosthesis users to control their devices more naturally by interpreting electrical signals from residual limb muscles. This technology represents a significant advancement over traditional switch-based control systems, offering a more fluid and responsive user experience. Hanger’s decision to acquire Coapt was a clear indication of its strategic intent to incorporate such high-level technological sophistication directly into its service offerings, thereby providing patients with access to state-of-the-art control solutions.
Liberating Technologies Inc. (LTI) was, at the time of the Coapt acquisition, a wholly-owned subsidiary of Coapt. This relationship meant that LTI’s innovative research, while distinct in its grant-funded focus and specific projects, was nevertheless operating under the broader corporate umbrella of Coapt. Therefore, when Hanger announced its acquisition of Coapt, it inherently included the eventual integration of LTI as part of the overall transaction.
The current announcement regarding the acquisition of LTI effectively finalizes this strategic consolidation. As stated by Hanger, "with this acquisition, the full Coapt portfolio is now a part of the Hanger family." This clarifies that all entities, intellectual property, and specialized teams associated with Coapt, including the groundbreaking research capabilities of LTI, are now fully integrated into Hanger’s operational structure. This comprehensive integration ensures that Hanger gains full control and synergy across Coapt’s commercialized products and LTI’s pioneering research pipeline.
This chronological approach to integration highlights a deliberate strategy by Hanger. By first acquiring Coapt, Hanger secured advanced, commercially viable control technologies that could be immediately deployed to improve patient care. Subsequently, by confirming the full integration of LTI, Hanger has simultaneously secured a powerful engine for future innovation. This two-pronged strategy allows Hanger to simultaneously enhance its current service offerings with proven technology and invest deeply in the research and development that will define the next generation of prosthetic solutions. It ensures that the continuum from fundamental research to clinical application is streamlined, robust, and driven by a unified vision for patient empowerment through technology.
Supporting Data and Technological Advancements
The core strength of Liberating Technologies Inc. lies in its capacity to conduct specialized, grant-funded research that addresses critical unmet needs in the O&P field. With the acquisition by Hanger, LTI’s team will continue to spearhead its current initiatives, which are poised to deliver transformative advancements in prosthetic functionality and user experience. These projects leverage sophisticated engineering and scientific principles to tackle complex challenges, promising significant improvements for prosthesis users.
One of LTI’s prominent initiatives focuses on advancing voice-recognition technology for improved prosthesis control. This research aims to move beyond traditional muscle signal-based control, offering an alternative or complementary input method that could significantly enhance the intuitiveness and versatility of prosthetic devices. Imagine a user able to articulate commands such as "grasp," "release," or "rotate wrist" and have the prosthesis respond accurately and immediately. This technology holds particular promise for individuals who may have limited or inconsistent muscle signals due to the nature of their amputation, or for tasks requiring a high degree of precision and cognitive load. The development involves complex algorithms to interpret vocal commands, filter out ambient noise, and translate speech into precise motor control signals for the prosthesis. The potential benefits include reduced cognitive effort, faster task completion, and a more natural interaction with the artificial limb, ultimately fostering greater independence and functional capabilities.
Another vital area of LTI’s research involves developing socket cooling systems to support residual limb skin health. The interface between the residual limb and the prosthetic socket is a critical point of contact, often prone to issues such as heat buildup, sweating, skin irritation, and breakdown. These problems can lead to discomfort, pain, and even necessitate downtime from prosthesis use, severely impacting a user’s quality of life. LTI’s work in this domain seeks to engineer active or passive cooling mechanisms integrated directly into the prosthetic socket. This could involve micro-fans, thermoelectric coolers, or advanced materials with superior heat dissipation properties. By regulating temperature and managing moisture, these systems aim to prevent dermatological complications, enhance comfort, and extend the duration for which a prosthesis can be comfortably worn. This research directly addresses a fundamental challenge in prosthetic design, moving beyond mere functionality to prioritize the long-term health and well-being of the residual limb.
Furthermore, LTI is dedicated to optimizing electrode configurations for pattern recognition control to help prosthesis users achieve optimal functional outcomes. Building on the foundational work in pattern recognition, this research delves into the precise placement, number, and type of electrodes used to detect electromyographic (EMG) signals from residual muscles. Pattern recognition algorithms interpret these complex muscle signals to predict the user’s intended movement, allowing for more intuitive control of multi-articulating prostheses. LTI’s optimization efforts are crucial for maximizing the accuracy, reliability, and responsiveness of these systems. This involves extensive experimentation and data analysis to determine the ideal electrode array that captures the most distinct and consistent muscle patterns, thereby reducing errors and improving the fluidity of movement. The goal is to make prosthetic control feel as natural and effortless as possible, enabling users to perform a wider range of activities with greater confidence and precision.
Beyond these specific projects, LTI’s commitment to "actively pursuing new research and development opportunities to expand the impact of their work" signifies a dynamic and forward-looking approach. This continuous pursuit of innovation, now coupled with Hanger’s extensive resources and clinical insights, promises to accelerate breakthroughs across the O&P spectrum. The ability to test these technologies within Hanger’s vast network of clinics will provide invaluable real-world data, accelerating the transition from laboratory prototype to clinical application. These initiatives, supported by government grants, represent not just academic exercises but strategic investments in technologies that have the potential to fundamentally redefine prosthetic care, empowering users with capabilities previously thought unattainable.
Official Responses and Synergistic Expectations
The official responses from Hanger’s leadership following the acquisition highlight both the strategic rationale and the anticipated synergies that this integration is expected to yield. These statements underscore a shared vision for advancing patient care through relentless innovation and evidence-based practice.
Pete Stoy, Hanger’s Chief Executive Officer, articulated the overarching strategic importance, stating, “The addition of LTI strengthens Hanger’s continued commitment to expanding research and development, advancing clinical practice, and improving patient outcomes through evidence-based care. This partnership also reflects our ambition to accelerate global technological progress for O&P patients and to join forces with current and future collaborators to drive the next generation of innovation.” Stoy’s comments are multifaceted. Firstly, they reaffirm Hanger’s foundational dedication to R&D as a core pillar of its growth and service model. This isn’t merely about acquiring technology but about fostering a culture of continuous inquiry and improvement. Secondly, the emphasis on "advancing clinical practice" and "improving patient outcomes through evidence-based care" speaks to Hanger’s patient-centric philosophy, ensuring that technological advancements are rigorously validated and demonstrably beneficial. Finally, the mention of "accelerating global technological progress" and "joining forces with current and future collaborators" points to Hanger’s broader leadership aspirations within the O&P industry, seeking to be a catalyst for innovation on an international scale, potentially through partnerships with academic institutions, other technology companies, and government agencies.
On the LTI side, Todd Farrell, PhD, who now serves as vice president of research and development for Hanger, expressed enthusiasm for the new chapter. “We are excited about this opportunity to become a part of the Hanger ecosystem, which will provide LTI with the technical resources, and the access to clinical insights and clinical data that can help us further drive and enhance innovation,” Dr. Farrell stated. His response is particularly insightful as it comes from within the acquired entity, highlighting the tangible benefits LTI anticipates from its new affiliation. The mention of "technical resources" suggests access to Hanger’s engineering expertise, infrastructure, and potentially funding beyond grant cycles, which can be critical for sustaining long-term research. Crucially, "access to clinical insights and clinical data" is a game-changer for a research organization. Researchers often work in controlled environments; direct feedback from clinicians and real-world data from thousands of patient interactions provide invaluable context, allowing LTI to refine its designs, identify new problem areas, and ensure that its innovations are truly relevant and effective for end-users. This direct pipeline from research to clinic and back again is the essence of synergistic expectation.
The synergy between Hanger’s extensive clinical network and LTI’s specialized research capabilities is expected to manifest in several key ways:
- Accelerated Translation: Hanger’s clinics will serve as invaluable testing grounds for LTI’s prototypes, enabling rapid iteration and refinement based on direct patient feedback and clinical observations. This significantly shortens the typical development cycle from laboratory to market.
- Data-Driven Research: Access to Hanger’s vast pool of de-identified patient data will provide LTI researchers with robust datasets to inform their designs, validate their hypotheses, and identify specific patient populations that could benefit most from particular technologies.
- Clinical Relevance: By being integrated into a patient care provider, LTI’s research will remain acutely focused on real-world clinical needs and challenges, ensuring that innovations are not only technologically advanced but also practically applicable and impactful for patients.
- Enhanced Funding Opportunities: The combined reputation and resources of Hanger and LTI may strengthen future grant applications, allowing for the pursuit of even more ambitious and impactful research projects.
- Expert Collaboration: LTI researchers will have direct access to Hanger’s clinicians, prosthetists, and orthotists – experts who intimately understand the daily lives and challenges of O&P patients. This collaborative environment will foster cross-pollination of ideas and expertise.
In essence, the official responses reflect a mutual recognition of how each entity’s strengths can amplify the other’s, creating a powerful engine for innovation that promises to redefine the future of orthotic and prosthetic care.
Broader Implications for Patient Care and the O&P Industry
The acquisition of Liberating Technologies Inc. by Hanger Inc. carries profound implications not just for the two organizations involved, but for the entire orthotics and prosthetics industry and, most importantly, for the millions of individuals who rely on prosthetic devices. This strategic consolidation is poised to redefine patient care, accelerate technological progress, and potentially elevate the standards of practice across the field.
One of the most immediate and significant implications for patient outcomes is the promise of faster access to more advanced, intuitive, and comfortable prosthetic technologies. LTI’s ongoing research into voice-recognition control, socket cooling systems, and optimized electrode configurations directly addresses critical pain points for prosthesis users: control, comfort, and skin health. By bringing these projects under Hanger’s wing, the path from research bench to patient delivery is streamlined. This means less waiting time for patients to benefit from breakthroughs that can significantly improve their daily functionality, reduce discomfort, and enhance their overall quality of life. For example, effective socket cooling could dramatically increase wear time, allowing individuals greater participation in work, recreation, and social activities without the debilitating effects of skin breakdown or excessive sweating.
The acquisition is also likely to foster a faster development cycle for new technologies. Research and development in medical devices can often be protracted, involving multiple stages of ideation, prototyping, testing, and regulatory approval. By integrating LTI’s research capabilities with Hanger’s extensive clinical network and patient data, Hanger can create an unparalleled feedback loop. Researchers can rapidly test prototypes in real-world clinical settings, gather immediate feedback from users and clinicians, and iterate on designs with unprecedented speed. This agile approach minimizes time-to-market for promising innovations, ensuring that patients receive the benefits of cutting-edge research sooner.
From an industry perspective, this move significantly strengthens Hanger’s market leadership in innovation. By acquiring a research powerhouse like LTI, Hanger solidifies its position as a frontrunner not just in providing care, but in shaping the future of O&P technology itself. This could set a new benchmark for other companies in the sector, potentially spurring increased investment in R&D across the board. The integration of high-level research capabilities directly into a patient care provider creates a vertically integrated innovation model, positioning Hanger uniquely to lead in both technological advancement and its clinical application.
The nature of LTI’s work, heavily reliant on government-funded grants, also highlights the critical role of public-private partnerships in driving medical innovation. These grants often support foundational research that might be too high-risk or long-term for purely commercial ventures. By acquiring LTI, Hanger is essentially investing in the outcomes of these publicly funded endeavors, providing the necessary commercial infrastructure to translate these scientific discoveries into widely accessible patient solutions. This model demonstrates a sustainable pathway for integrating cutting-edge academic and governmental research into practical healthcare solutions.
Looking ahead, the acquisition signals a future where prosthetic technology is not merely about replacing a limb, but about restoring capabilities, enhancing human potential, and integrating seamlessly into a user’s life. The focus on intuitive control, user comfort, and physiological health underscores a holistic approach to prosthetic design. It anticipates a future where prosthetic devices are smarter, more responsive, and more personalized, moving towards bionic integration that blurs the lines between natural and artificial. This commitment to "evidence-based care" further ensures that these advancements are not just technologically impressive, but clinically proven to deliver superior results for patients. The long-term implication is a significant uplift in the quality of life for individuals with limb loss, empowering them with greater independence, dignity, and participation in all aspects of society.
The Future Landscape of Prosthetic Innovation
The strategic integration of Liberating Technologies Inc. into Hanger Inc. represents a bold declaration of intent regarding the future of orthotics and prosthetics. This move is not merely an expansion of Hanger’s portfolio but a profound investment in shaping the very landscape of prosthetic innovation for decades to come.
The long-term vision emerging from this acquisition is one where the development of prosthetic technologies is intrinsically linked with deep clinical understanding and real-world patient needs. By housing LTI’s research within Hanger’s extensive clinical ecosystem, the traditional divide between laboratory science and practical application is significantly narrowed. This promises to accelerate the journey from groundbreaking discovery to widespread clinical availability, fostering a continuous cycle of innovation driven by both scientific curiosity and patient-centric imperatives.
One of the key aspects of this future landscape will be the relentless pursuit of enhanced user experience. As LTI continues its work on voice recognition and optimized pattern recognition, the goal is to make prosthetic control so intuitive that it becomes an extension of the user’s own will, minimizing cognitive load and maximizing natural movement. This could involve further integration with neuro-interfacing technologies, advanced sensors, and artificial intelligence to create prostheses that learn and adapt to individual user preferences and environmental contexts. The focus will shift from merely enabling basic function to restoring nuanced movement and sensory feedback.
Furthermore, the emphasis on residual limb health and comfort, exemplified by LTI’s socket cooling research, points towards a future where prostheses are designed with an unparalleled understanding of biomechanics and material science. Innovations in smart materials, adaptive interfaces, and personalized fit technologies will aim to virtually eliminate common issues like skin irritation, pressure sores, and discomfort, allowing for prolonged and more active use of devices. This will involve advanced manufacturing techniques, such as 3D printing, to create highly customized sockets that precisely conform to the unique anatomy of each residual limb, coupled with intelligent systems that monitor skin conditions and provide real-time feedback.
The "Hanger ecosystem" — comprising Hanger Ventures, the Hanger Institute, and now LTI — will serve as a powerful engine for interdisciplinary collaboration. This environment will attract top talent from diverse fields, including biomedical engineering, data science, rehabilitation medicine, and materials science, to collectively address complex challenges. The synergy created by these varied perspectives, coupled with Hanger’s access to vast clinical data and patient insights, will foster breakthroughs that transcend traditional disciplinary boundaries.
However, the future landscape also presents challenges. Ensuring that these advanced technologies remain accessible and affordable for a broad patient population will be crucial. Navigating regulatory pathways for novel medical devices, managing the complexities of insurance reimbursement, and ensuring equitable access to care will require ongoing advocacy and strategic planning. Hanger’s experience as a large provider places it in a strong position to address these challenges, advocating for policies that support innovation and patient access.
Ultimately, the acquisition of Liberating Technologies Inc. solidifies Hanger’s commitment to a future where orthotic and prosthetic solutions are not just devices, but integral tools that empower individuals to live full, active, and unconstrained lives. By investing in foundational research and committing to its translation into practical, evidence-based care, Hanger is not just preparing for the future of prosthetic innovation; it is actively building it, one breakthrough at a time. The impact will be measured not just in technological advancements, but in the countless lives transformed through enhanced mobility, comfort, and independence.
